Paul Waring
Overview
Explore the profile of Paul Waring including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
4740
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan T, Fink J, Tay T, Jaradi B, Stone N, Waring P, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200309.
PMID: 36331241
No abstract available.
2.
Aziz D, Lee C, Chin V, Fernandez K, Phan Z, Waring P, et al.
J Pathol Clin Res
. 2022 Apr;
8(4):355-370.
PMID: 35384378
Basal-like breast cancer (BLBC) has a greater overlap in molecular features with high-grade serous ovarian cancer (HGSOC) than with other breast cancer subtypes. Similarities include BRCA1 mutation, high frequency of...
3.
Aziz D, Portman N, Fernandez K, Lee C, Alexandrou S, Llop-Guevara A, et al.
NPJ Breast Cancer
. 2021 Sep;
7(1):111.
PMID: 34465787
Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin...
4.
Brinkmann K, Waring P, Glaser S, Wimmer V, Cottle D, Tham M, et al.
EMBO J
. 2020 Nov;
39(24):e105561.
PMID: 33236795
Studies of gene-targeted mice identified the roles of the different pro-survival BCL-2 proteins during embryogenesis. However, little is known about the role(s) of these proteins in adults in response to...
5.
Loree J, Dowers A, Tu D, Jonker D, Edelstein D, Quinn H, et al.
Clin Cancer Res
. 2020 Oct;
27(1):52-59.
PMID: 33087330
Purpose: Expanded mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed...
6.
Aziz D, Etemadmoghadam D, Caldon C, Au-Yeung G, Deng N, Hutchinson R, et al.
Gynecol Oncol
. 2018 Sep;
151(2):327-336.
PMID: 30209015
Objectives: Readily apparent cyclin E1 expression occurs in 50% of HGSOC, but only half are linked to 19q12 locus amplification. The amplified/cyclin E1 subset has intact BRCA1/2, unfavorable outcome, and...
7.
Lee B, Tran B, Hsu A, Taylor G, Fox S, Fellowes A, et al.
Intern Med J
. 2018 Apr;
48(7):786-794.
PMID: 29607586
Background: Technology has progressed from single gene panel to large-scale genomic sequencing. This is raising expectations from clinicians and patients alike. The utility and performance of this technology in a...
8.
Pearson H, Li J, Meniel V, Fennell C, Waring P, Montgomery K, et al.
Cancer Discov
. 2018 Mar;
8(6):764-779.
PMID: 29581176
Genetic alterations that potentiate PI3K signaling are frequent in prostate cancer, yet how different genetic drivers of the PI3K cascade contribute to prostate cancer is unclear. Here, we report mutation/amplification...
9.
OReilly L, Putoczki T, Mielke L, Low J, Lin A, Preaudet A, et al.
Immunity
. 2018 Mar;
48(3):570-583.e8.
PMID: 29562203
Polymorphisms in NFKB1 that diminish its expression have been linked to human inflammatory diseases and increased risk for epithelial cancers. The underlying mechanisms are unknown, and the link is perplexing...
10.
Lunke S, Lee B, Kranz S, Gibbs P, Waring P, Christie M
J Clin Pathol
. 2017 Mar;
70(8):720-723.
PMID: 28314739
Activating mutations in and genes in patients with colorectal cancer (CRC) are associated with a lack of response to treatment with anti-epidermal growth factor receptor (EGFR) therapies. Mutations in these...